69 results about "Disease gene" patented technology

The invention provides a topology and biological feature fusion-based virulence gene prediction method, which comprises the following steps of: obtaining a to-be-detected gene; inputting the to-be-detected gene into a trained DAVGAE model, and predicting the correlation degree of the to-be-detected gene and the disease to obtain a disease gene correlation prediction conclusion; wherein the DAVGAE model comprises a data enhancement module, an encoder and an inner product decoder. The problems of data sparsity and heterogeneous data integration in gene-disease association prediction can be effectively solved at least through a DAVGAE model formed by a data enhancement module, an encoder and an inner product decoder.

The invention provides a method for predicting miRNA-lncRNA-disease ternary correlation through deep tensor decomposition and hypergraph convolution, and relates to the technical field of miRNA-lncRNA-disease ternary correlation prediction. Comprising six steps of integration of multi-source heterogeneous data, generation of three-dimensional tensor representation, hypergraph convolution modeling high-order interaction, graph attention network feature refining, depth graph convolution network enhancement and correlation prediction. Node features in a graph attention self-adaptive refining similarity network are integrated, global structure learning is enhanced by adopting a depth graph convolutional network, and the combination can generate stable and information-rich embedding for final ternary correlation prediction, so that potential complex correlation among various biological entities such as diseases, genes and drugs can be accurately extracted, and the prediction accuracy is improved. The potential relation and mechanism between the biological entities are further disclosed, and comprehensive ternary correlation prediction is achieved.

The invention discloses a method, a device, equipment, a medium and a product for evaluating the effect of traditional Chinese medicine on diseases, and relates to the technical field of pharmacology of traditional Chinese medicine, the method comprises the following steps: acquiring a disease data set and a traditional Chinese medicine data set of a target disease; extracting a disease target entity from the disease data set by adopting a large language model, and extracting a medicinal material entity from the traditional Chinese medicine data set; constructing a disease gene network according to each disease target entity and a Barabas PPI network; constructing a medicinal material gene network according to the target traditional Chinese medicine formula, the medicinal material entities and a Barabas PPI network; the similarity between the disease gene network and the medicinal material gene network is calculated, the similarity is used for representing the effect of the target traditional Chinese medicine formula on the target disease, and quantitative evaluation of the effect of the traditional Chinese medicine on the disease can be achieved.

The invention discloses a specific molecular marker linked with a wheat powdery mildew resistance gene PmCad as well as an identification primer and application of the specific molecular marker, and relates to the technical field of biotechnology and genetic breeding. The molecular marker comprises a molecular marker 2BS509-2 and a molecular marker 2BS509-7. The nucleotide sequence of the molecular marker 2BS509-2 is as shown in SEQ ID NO. 1, and the nucleotide sequence of the molecular marker 2BS509-7 is as shown in SEQ ID NO. 2. The invention also provides an identification primer for identifying the molecular marker, and the nucleotide sequences of the identification primer are shown as SEQ ID NO.3, 4, 5 and 6. The identification primer can also be used for preparing a kit, can be used for identifying the powdery mildew-resistant character of wheat and creating a powdery mildew-resistant wheat strain, and has a potential application prospect in the field of wheat breeding.

The invention discloses a Cg12n-v4.6 nuclease. The amino acid sequence of the nuclease is as shown in SEQ ID No. 12. The invention also discloses a preparation method of the nuclease. The Cg12n-v4.6 nuclease mutant with increased activity and improved editing efficiency is developed, and the editing efficiency of the Cg12n-v4.6 nuclease mutant is up to 70% or above. Meanwhile, through engineering modification of corresponding sgRNA of Cas12n, the size of the sgRNA skeleton is reduced. An enhanced Cas12n gene editing tool, namely an eCg12n gene editing system, is developed by combining an engineered Cg12n-v4.6 nuclease mutant and a simplified sgRNA skeleton. Meanwhile, by fusing deaminase, a compact cytosine base editor and a compact adenine base editor are constructed, and the cytosine base editor is applied to edit and induce disease genes to generate early termination codons, so that safe knockout of the genes is realized. Compared with an original wild type editing system, the Cg12n-v4.6 nuclease mutant and a compact eCg12n gene editing system derived from the Cg12n-v4.6 nuclease mutant have the advantages that the editing efficiency is improved, the system size is further simplified, and the Cg12n-v4.6 nuclease mutant and the compact eCg12n gene editing system derived from the Cg12n-v4.6 nuclease mutant are more suitable for gene editing application.

The invention belongs to the technical field of biological medicines, and particularly relates to application and a method of PHF20 in preparation of a medicine for treating systemic lupus erythematosus and the medicine. The invention discloses an application of PHF20 in treatment of systemic lupus erythematosus, a lentivirus with murine PHF20 is selected as a gene therapy tool, an R848 induced lupus mouse model is taken as an experimental subject for gene therapy, and results show that injection of the overexpressed PHF20 lentivirus in a lupus mouse body has the following effects: (1) spleen swelling is improved, and spleen index is significantly reduced; (2) reducing urine protein, urea nitrogen level, anti-dsDNA antibody level and IgG antibody level of the model mouse; and (3) the pathological damage to the kidney of the model mouse is relieved. The research results show that the PHF20 serving as the target provides important reference value for potential application prospects in systemic lupus erythematosus gene therapy and even autoimmune disease gene therapy.

The application discloses a traditional Chinese medicine compound analysis method based on a multi-dimensional data and information weighted network, and belongs to the field of traditional Chinese medicine compound analysis. The method comprises the following steps: constructing a multi-dimensional disease gene set; acquiring a traditional Chinese medicine compound set and a target set; determining disease gene nodes, compound nodes and target nodes respectively, and constructing a heterogeneous correlation network; performing propagation node screening on the heterogeneous correlation network, and weighting the edge set of the heterogeneous correlation network; running three algorithms on the updated heterogeneous correlation network respectively, and performing equal-weight average fusion on the propagation results of the three algorithms to obtain a final weighted network correlation degree score; sorting the final weighted network correlation degree score from high to low to obtain a key target candidate list; and selecting the first N candidate targets in the key target candidate list for enrichment analysis. The application solves the problems of single data source, lack of functional semantic support in network construction, static node evaluation index, and disconnection between enrichment analysis and core algorithm in the prior art.

This invention relates to the packaging and screening of viral vectors, particularly to the packaging and screening of AAV mutants, specifically an adeno-associated virus mutant that efficiently infects HT-22 cells. By constructing a peptide mutant library of AAV9, a new AAV9 mutant with seven inserted amino acids was obtained through screening and verification. This mutant can effectively infect HT-22 cells at an MOI of 1E+5, achieving a higher infection rate than the natural AAV9 serotype at MOI=1E+5. The AAV9-HT01 mutant obtained after screening showed the best effect, with a significantly higher infection positivity rate compared to the control AAV9 serotype under the same MOI conditions. The fold increase was 4.4-fold as measured by luciferase (RLU) value detection. This effectively reduces the amount of AAV cells used for infection, saving experimental costs, and simultaneously makes it feasible to study the mechanisms of gene therapy for central nervous system diseases in HT-22 cells.

The application discloses a kind of preparation and application of multi-target small nucleic acid drug based on small activation RNA technology, and is related to the field of biotechnology.The preparation method of the multi-target small nucleic acid drug includes the following steps: (1) selecting at least two anti-disease genes according to target disease;(2) intercepting the sequence of 1000 base pairs of the promoter region upstream of the coding region of the anti-disease gene;(3) according to the promoter sequence, avoid CpG island and locate the segment of species conservation, and cut a sequence containing 19 base length as a sense strand;(4) design an antisense strand according to the sense strand, and the 19 base of the antisense strand and the sense strand are completely complementary;(5) add two deoxythymine or uracil to the 3' end of each chain.The multi-target small nucleic acid drug has good therapeutic effect on heart failure, and has strong cancer cell killing ability and inhibition ability of cancer cell migration, and has wide application prospect.

The invention discloses a biomolecular interaction prediction method based on multi-modal attention fusion, and belongs to the technical field of artificial intelligence drug discovery. The method comprises the following steps: acquiring multi-modal characteristics of drugs, targets, diseases and genes: sequence structure characteristics, 3D structure characteristics, similarity network characteristics and biological relation network embedding characteristics; constructing a feature fusion prediction model, and performing training; inputting the multi-modal features of the two biological entities into the trained feature fusion prediction model, and outputting the probability of interaction of the two biological entities; the feature fusion prediction model comprises a Transform encoder and an MLP (Markup Language Protocol) network; the multi-modal features are input into a feature fusion prediction model for stacking and then are input into a Transform encoder, the features are processed by using a multi-head self-attention mechanism, and an output result is flattened and subjected to dimension reduction processing to obtain embedded vector representation; and finally, performing element corresponding multiplication on the embedded vectors of the two biological entities, inputting the embedded vectors into an MLP network, and outputting an interaction probability between the two biological entities.

The present application relates to the technical field of gene detection, in particular to a primer probe combination for detecting Alzheimer's disease, a product and application thereof. The primer probe combination and kit provided by the present application can simultaneously detect Alzheimer's disease gene mutation and methylation, can effectively distinguish Alzheimer's disease patients from non-Alzheimer's disease subjects, realize low-invasive, low-cost, high-sensitivity, high-specificity detection of Alzheimer's disease, the total sensitivity of the blood sample for detecting Alzheimer's disease can reach 88.89%, the specificity of the blood sample for detecting non-Alzheimer's disease can reach 95.74%, the detection probability of false negative results can be reduced, and the detection accuracy is high.

The invention relates to a conjugate for transferring an effector molecule from outside a cell into said cell, the conjugate comprising at least one effector molecule to be transferred into the cell, at least one saponin of the mono-desmosidic triterpene glycoside type or the bi-desmosidic triterpene glycoside type, and at least one single-domain antibody (sdAb), covalently bound to each other, wherein the sdAb is capable of binding to a cell-surface molecule of said cell. The invention also relates to a pharmaceutical composition comprising the conjugate of the invention. Furthermore, the invention relates to a pharmaceutical composition of the invention, for use as a medicament. In addition, the invention relates to a pharmaceutical composition of the invention, for use in the treatment or the prophylaxis of any one or more of: a cancer, an auto-immune disease such as rheumatoid arthritis, an enzyme deficiency, a disease related to an enzyme deficiency, a gene defect, a disease relating to a gene defect, an infection such as a viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, an amyloidosis and transthyretin-mediated amyloidosis. The invention also relates to an in vitro or ex vivo method for transferring the conjugate from outside a cell to inside said cell or for transferring the effector molecule comprised by the conjugate of the invention from outside a cell to inside said cell, preferably to the cytosol of said cell.

The invention relates to the technical field of biology, in particular to a vitis davidii susceptible gene VdTLP19 as well as an encoding protein and application of the vitis davidii susceptible gene VdTLP19. The vitis davidii susceptible gene VdTLP19 is located on a chromosome 2 of vitis davidii and is distributed in a region 3655997-3656642, and the nucleotide sequence of the vitis davidii susceptible gene VdTLP19 is shown as SEQ ID No.1. The amino acid sequence of the protein coded by the gene is as shown in SEQ ID No.2. And after the vitis davidii susceptible gene VdTLP19 is silenced, the resistance of grape fruits to pathogenic bacteria is enhanced. After the VdTLP19 gene provided by the invention is silenced, the resistance of grapes to anthracnose can be improved, and a theoretical basis is provided for grape anthracnose resistance breeding.

The application provides a nucleic acid test strip and a detection method for detecting smut genes, and belongs to the technical field of detection. The application comprises a bottom plate, a sample pad and a water absorption pad; an NC film is attached to the bottom plate, the NC film is provided with a T line and a C line, the T line is sprayed with a coupling agent of a capture probe and streptavidin; the C line is sprayed with a coupling agent of a quality control probe and streptavidin; the quality control probe is complementary to a DNA sequence of a DNA1-AgInS2 / ZnS fluorescent probe. The application utilizes the advantages of AgInS2 / ZnS quantum dots (AgInS2 / ZnS QDs), such as good biocompatibility, high fluorescence intensity and wide spectral range. The test strip based on AgInS2 / ZnS quantum dots has higher sensitivity and stronger quantitative capacity than traditional test strips. The fluorescence ratio of the T line and the C line is detected by using a fluorescence immunoassay instrument for quantitative detection, the fluorescence immunoassay instrument can quickly read out the value, and has the advantages of rapidness, simple operation, low sensitivity, good selectivity and the like.

The present invention provides a novel gene-therapeutic agent for neurodegenerative diseases. The present invention allows AB variants to be secreted out of cells and continuously supplies tau inhibitor peptides in the cells to allow wt Aβ polymerization and wt tau polymerization to be slowed or inhibited and cytotoxicity to be reduced in the human body, and thus exhibits excellent effects of preventing, alleviating, and treating neurodegenerative diseases.

Provided is a platform for expressing a protein of interest by artificially manipulating the liver, and more particularly, to a platform for alleviating or treating a genetic disorder or improving a body function by inducing expression by inserting a transgene (e.g., a therapeutic gene) which can function or be expressed normally, into a high-expression secretory gene, instead of a disease gene which functions or is expressed abnormally. The high-expression secretory gene includes the HP or APOC3 gene. The transgene includes one that is highly expressed using a promoter in a hepatocyte genome and is secretory out of the cell.

The utility model relates to the technical field of gene detection, in particular to an autoimmune disease gene detection device which comprises two supporting frames fixedly installed at the top of a base, first electric telescopic rods are fixedly installed on the inner sides of the supporting frames, and first movable plates are installed at the output ends of the first electric telescopic rods. A first movable plate is driven by a first electric telescopic rod, so that the first movable plate is in sealed butt joint with a protection frame, a kit above the first movable plate is protected, reagents in the kit are better isolated from the outside, a round hole is shielded and sealed by a baffle, the kit can be isolated from the outside when detection is not carried out, and the detection efficiency is improved. By arranging a second protective shell and a baffle, the detection chip can be isolated and protected, so that the detection chip and the kit are independently protected, cross contamination between the detection chip and the kit is reduced, the accuracy of the detection device is improved, and a final detection result is effective.

The invention provides application of a DTX29 gene and a protein thereof in improving the resistance of plants to phytophthora infestans. The invention finds a susceptible gene DTX29 capable of effectively improving the resistance of plants to phytophthora infestans through a large number of researches. The DTX29 gene of the plant is edited through a CRISPR-Cas technology and the like, so that the function of the DTX29 gene is lost, the resistance of the plant to phytophthora infestans can be effectively improved, the diameter and area of disease spots and the relative biomass of phytophthora infestans are reduced, and normal growth and development of the plant are not influenced. The invention provides a new target and idea for prevention and control of plant diseases caused by phytophthora infestans.

The invention relates to a disease similarity prediction method and system based on multivariate data fusion, and the method comprises the steps: collecting gene network data, miRNA network data, a disease-gene incidence matrix and a disease-miRNA incidence matrix, and forming a unified heterogeneous biological network; extracting and generating a multi-modal feature set through the graph convolutional network and the improved graph attention network; the independent weight of each feature in the multi-modal feature set is calculated through a multi-layer perceptron, gene view angle embedding and miRNA view angle embedding of the disease are generated in combination with the incidence matrix and serve as model input training, and a lightweight bilinear tower model is obtained; model parameters are optimized through an alternate training strategy and a regularization mechanism inspired by ReconBoost, an optimized lightweight bilinear tower model is obtained, and a similarity prediction result of the target disease pair is obtained. The defects of multivariate data integration, sparse data processing and prediction stability in the prior art are effectively overcome.

The invention discloses an application of a rice susceptible gene Os10g0506100 and an encoding protein thereof in regulation and control of plant disease resistance. The nucleotide sequence of the rice susceptible gene Os10g0506100 is as shown in SEQ ID NO: 1, and the coded protein sequence is as shown in SEQ ID NO: 2. The Os10g0506100 gene is knocked out in rice through an RISPR / Cas9 technology, it is found that the resistance of rice to rice blast can be remarkably improved through knockout of the gene, and an effective way can be provided for rice breeding and disease-resistant variety improvement.

The invention discloses an application of a black spot resistant gene PuSAP3 in plant disease-resistant genetic breeding. The gene PuSAP3 containing the A20 / AN1 type zinc finger transcription factor is separated and cloned from a disease-resistant germplasm, namely pyrus ussuriensis, and the sequence of the gene PuSAP3 is as shown in SEQ ID NO. 1. The gene is used for respectively constructing an over-expression vector and a silent vector, and the over-expression vector and the silent vector are introduced into pear seedlings through an agrobacterium tumefaciens-mediated genetic transformation method to respectively obtain a stably expressed over-expression strain and a TRV-mediated silent strain for disease-resistant function analysis. The result shows that the PuSAP3 transcription factor gene obviously improves the pathogenic bacterium resistance of the plant. Exploration of the gene provides important potential gene resources for plant disease-resistant molecular breeding, provides new insight for disease-resistant breeding of fruit trees and even other crops, and provides assistance for implementation of green agriculture in China.

The invention discloses an InDel molecular marker related to maize rough dwarf disease resistance and application of the InDel molecular marker, and belongs to the technical field of molecular genetics. The InDel molecular marker closely linked with the maize rough dwarf virus resistance gene is obtained by screening in 12, 857, 147-13, 124 and 718 bp regions of the maize chromosome 2, the resistance of maize to rough dwarf virus can be accurately identified in an early stage by utilizing the InDel molecular marker, and the InDel molecular marker has the advantages of simplicity, convenience, rapidness, high efficiency, accuracy, good repeatability, high specificity and the like; the method can be used for corn molecular marker-assisted breeding.

The present disclosure provides recombinant vectors encoding a choline acetyltransferase (ChAT) polypeptide, compositions thereof, and methods of use thereof.

The invention belongs to the technical field of sunflower molecular breeding, and particularly relates to a KASP molecular marker related to a sunflower sclerotiniose resistance gene, a primer and application of the KASP molecular marker in sunflower disease resistance breeding. The KASP molecular marker related to the sunflower sclerotiniose resistance gene is a nucleotide sequence as shown in SEQ ID NO.1; the KASP molecular marker can be combined with primers SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, and through KASP molecular marker detection, whether a sunflower sample to be detected carries the sclerotiniose-resistant gene or not can be accurately judged, and the breeding process of sunflower sclerotiniose-resistant breeding is accelerated.

The present invention discloses a gene expression pattern discovery system and method based on information entropy. The system comprises: an acquisition module for acquiring disease samples of multiple different cancers and normal samples of z1 types of cancer among the multiple different cancers; each sample comprises expression values of multiple different genes and annotations of each gene; a preprocessing module for preprocessing the disease samples and normal samples respectively; a mapping module for performing batch processing, outlier processing, mapping and conversion on the preprocessed disease samples and preprocessed normal samples to map the expression values onto visible light, thereby obtaining a disease gene expression spectrum for each cancer and a normal gene expression spectrum for each cancer among the z1 types of cancer; a construction module for acquiring prior expression data of different human tissues to construct a gene co-expression network; and a prediction module for predicting lncRNA genes associated with each cancer based on the disease gene expression spectrum, the normal gene expression spectrum and the gene co-expression network.

The invention belongs to the technical field of gene engineering, and relates to application of a wheat negative regulation anti-disease gene TaZF10 in resisting gibberellic disease. The invention verifies that the gene TaZF10 negatively regulates the resistance of wheat to gibberellic disease, the protein TaZF10 coded by the gene TaZF10 interacts with gibberellic disease resistant protein TaSnRK1 alpha, and the TaSnRK1 alpha interferes with the stability of the TaZF10 protein. The gene TaZF10 is subjected to frameshift mutation through a CRISPR-Cas9 gene editing technology, so that the protein TaZF10 loses functions, a gibberellic disease resistant material is created, and an effective way and material reserve are provided for wheat disease resistance breeding and disease prevention and control.

The present application relates to the technical field of genetic engineering, in particular to two Cynoglossus semilaevis anti-vibrio disease genes and application methods. The present application mainly studies the role of CD79a and CD79b in Cynoglossus semilaevis in resisting vibrio disease, and verifies from two directions of in vivo and in vitro, further promotes the progress of Cynoglossus semilaevis disease resistance breeding, and shows that CD79a and CD79b have the role of inhibiting Vibrio harveyi.

The invention discloses a molecular marker closely linked with a wheat powdery mildew resistance gene PmJ684 and application of the molecular marker, and relates to the technical field of biological genetic engineering. The molecular marker is YTULL-40, and the molecular marker is a molecular marker The nucleotide sequence of an upstream primer of the marker is as shown in SEQ ID NO: 1; the nucleotide sequence of the downstream primer is as shown in SEQ ID NO: 2; the molecular marker is used for carrying out PCR (Polymerase Chain Reaction) amplification on to-be-detected wheat genome DNA (Deoxyribonucleic Acid) to obtain a corresponding amplification product with the molecular weight of 172bp. According to the molecular marker YTULL-40 closely linked with the wheat powdery mildew resistance gene PmJ684, provided by the invention, a PmJ684 genetic mapping group can be accurately detected, and fine positioning and cloning of the PmJ684 are facilitated. Besides, the marker is used for assisted breeding, germplasm materials with the powdery mildew resistance gene PmJ684 can be accurately selected, the breeding period is shortened, and convenience is provided for wheat breeding.

The invention relates to a primer group, a kit and a method for detecting a Fabry cardiomyopathy genetic susceptibility gene, and belongs to the technical field of gene detection. The genetic susceptibility gene of the Brie cardiomyopathy is a GLA gene, and the mutation site of the genetic susceptibility gene is c.640-801Ggt; a; the primer group comprises a PCR (Polymerase Chain Reaction) amplification primer group, and the amplification primer group comprises a forward PCR amplification primer and a reverse PCR amplification primer; the primer group further comprises a Sanger sequencing primer group, and the sequencing primer group comprises a forward sequencing primer and a reverse sequencing primer. The invention also provides a kit and a detection method based on the primer group. According to the primer group and the kit containing the primer group, the c.640-801Ggt of the Fabry cardiomyopathy GLA gene can be detected on the basis of a first-generation sequencing technology; a site mutation has important value for early screening detection and genetic risk assessment of the disease gene.

This invention relates to the packaging and screening of viral vectors, particularly to the packaging and screening of AAV mutants, specifically adeno-associated virus mutants that efficiently infect HT-22 cells. By constructing a peptide mutation library of AAV2, new AAV2 mutants, AAV2-HT01 and AAV2-HT02, with seven amino acids inserted, were obtained through screening and verification. Specifically, AAV2-HT01 inserts the amino acid fragment MSTVGKD at positions 587-588 of the AAV2 capsid protein; AAV2-HT02 inserts the amino acid fragment VQGRVHE at positions 587-588 of the AAV2 capsid protein. These mutants can effectively infect HT-22 cells at an MOI of 1E+5, achieving a higher infection rate than the natural AAV2 serotype at MOI=1E+5. This effectively reduces the amount of AAV-infected cells used, saving experimental costs, and makes it feasible to study the mechanisms of gene therapy for central nervous system diseases in HT-22 cells.